Skip to content

Clinical study on the treatment of sudden deafness of kidney-essnce with Quanduzhong Capsule

Clinical study on the treatment of sudden deafness of kidney-essnce with Quanduzhong Capsule

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075204
Enrollment
Unknown
Registered
2023-08-29
Start date
2023-08-31
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden deafness of kidney-essnce

Interventions

Test group(first stage):Quanduzhong Capsule+Glucocorticoid
Control group(first stage):Quanduzhong Capsule stimulant+Glucocorticoid
Test group(second stage):Quanduzhong Capsule+Prednisone+Intratympanic injection+Hyperbaric oxygen
Control group(second stage):Quanduzhong Capsule stimulant+Prednisone+Intratympanic injection+Hyperbaric oxygen

Sponsors

Jiangsu Taizhou People‘s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1: Comply with the diagnostic standards of Western medicine for sudden deafness and traditional Chinese medicine for kidney essence deficiency 2: Classified as mild or moderate or moderate to severe deafness 3: The classification of deafness is low frequency descending type, high frequency descending type, or flat descending type 4: 18-70 years old, male or female 5: Subjects volunteer to sign an informed consent form and have a correct understanding of the significance of the study.

Exclusion criteria

Exclusion criteria: 1: Classified as severe or total deafness 2: The classification of deafness is total deafness 3: Subjects with dizziness 4: Deafness caused by a clear etiology (such as conductive deafness, mixed deafness), such as caused by taking drugs with ototoxicity, trauma, explosive stimulation, long-term exposure to noise environments, otitis media, Meniere's disease, acoustic neuromas, and genetic causes 5: Blood pressure in the consulting room: systolic pressure 9.0 mmol/L.

Design outcomes

Primary

MeasureTime frame
Clinical Symptom Grading Quantitative Score;

Secondary

MeasureTime frame
Improvement of listening ability;MCP-1?RANTES?sICAM-1?IL-8;Recovery rate and effective rate;

Countries

China

Contacts

Public ContactJiusheng Chu

Jiangsu Taizhou People‘s Hospital

taizhoucjs@163.com+86 139 5261 3580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026